Solid Biosciences and Phlox Therapeutics have formed a strategic collaboration focused on genetic cardiac diseases. The research collaboration will target a severe form of genetic dilated cardiomyopathy (DCM) for which there is currently a significant unmet need for effective treatments.
The strategic collaboration will integrate Solid Biosciences’ vector biology, manufacturing capabilities and drug development experience with Phlox’s deep expertise in genetic cardiomyopathies and RNA therapeutics. The companies will collaborate to develop novel precision genetic medicines for this form of DCM.
“This collaboration with Phlox Therapeutics is an exciting opportunity to work with a company that shares our commitment and innovative approach to bringing transformative therapies to patients with rare genetic diseases,” said Bo Cumbo, president and Chief Executive Officer of Solid Biosciences.
“Our pipeline of programs focused on neuromuscular and cardiac rare disease gives us deep insight into the diverse and complex nature of dilated cardiomyopathy. We look forward to a successful partnership with the Phlox team and executing on our joint vision to develop new therapies for patient populations for which there is high unmet medical need.”
”We are delighted to work with Solid Biosciences, a company with an exceptionally strong team and the innovative tools and technology we believe necessary to help deliver smartly designed RNA molecules to the heart,” said professor Yigal Pinto, MD, chief medical officer of Phlox Therapeutics.
“This collaboration is designed to accelerate the development of solutions for many of my patients who struggle with a cardiomyopathy for which there are no disease-modifying therapies. We believe the advanced RNA technology and human disease models of Phlox Therapeutics perfectly partner with the delivery tools Solid Biosciences brings to this collaboration.”
The strategic research collaboration will also be supported in part by a grant from the Dutch Top Sector Life Sciences and Health, a coalition that fosters public-private research and development partnerships that aim to develop innovative healthcare products and services.
